Plain-English translation of NCT06190067 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications — azacitidine and PD-1 therapy — to see if they work better together for treating Hodgkin lymphoma that has returned or stopped responding to previous treatment. Researchers want to measure how well the medication works, how long people stay healthy, and what side effects occur. This is an early-stage study with 40 participants.
Hodgkin lymphoma that comes back or doesn't respond to standard treatment is very difficult to manage, and patients urgently need new options. This trial is exploring whether combining these two medications in a new way might help people whose cancer has proven resistant to earlier therapies.
You likely qualify if…
You likely don't qualify if…
You would receive azacitidine and PD-1 therapy as part of this study, with regular visits to the hospital or clinic for treatment and monitoring. The research team will track how well the medication works, check your blood counts and organ function regularly, and watch for any side effects. You'll need to be willing to follow the study schedule and stay in close contact with the research team throughout your participation.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Navy General Hospital, Beijing
Enrollment target
~40 participants
Started
October 2023
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Liren Qian, PhD
Navy General Hospital, Beijing
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.